AbCellera (ABCL): Among the Stocks That Could 10x Over the Next 5 Years [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
Inc. (NASDAQ:ABCL) outlined its vision at the KeyBanc Capital Markets Healthcare Forum 2026, emphasizing its transition to a mid- to late-stage biotech with significant drug discovery capabilities. The company boasted a strong financial position, with around $700 million in cash and a three-year runway supported by government funding. Its annual cash burn of $120 to $130 million also funds early-stage development across many programs. The AbCellera Biologics Inc. (NASDAQ:ABCL) pipeline is also in focus, which includes ABCL635, currently in Phase 2 trials for the non-hormonal treatment of hot flashes, with potential development into cancer-related applications. ABCL575 is in Phase 1 testing for immunological diseases, with plans for further collaborations. Meanwhile, on February 24, AbCellera Biologics Inc. (NASDAQ:ABCL) announced earnings per share of -0.03, compared to an expected loss of $0.18, reflecting an 83.33% earnings outperformance. Its revenue climbed by $39.80 milli
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026Business Wire
- CRA: Here's the TFSA Contribution Room for 2026 and Why Now Is the Best Time to Use It [Yahoo! Finance Canada]Yahoo! Finance Canada
- AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3 at Forum [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M [Yahoo! Finance]Yahoo! Finance
ABCL
Earnings
- 2/24/26 - Beat
ABCL
Sec Filings
- 3/2/26 - Form 4
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- ABCL's page on the SEC website